Please login to the form below

Not currently logged in
Email:
Password:

Lux withdraws Luveniq application

Lux Biosciences has ceased its application for Luveniq to be approved in the EU to treat inflammation of the eye

Lux Biosciences has ceased its application for Luveniq to be approved in the EU to treat inflammation of the eye.

The US-based biopharma had intended the investigational treatment to be used in patients with chronic non-infectious uveitis involving the posterior or intermediate segments of the eyes.

Lux said it was unable to demonstrate to the satisfaction of the Committee for Medicinal Products for Human Use (CHMP) that the benefits of Luveniq outweigh its risks.

The application for the marketing authorisation for Luveniq was initially submitted to the European Medicines Agency (EMA) in Febraury, 2010, and the medicine received a negative opinion by the CHMP on June 23, 2011.

Lux submitted a re-examination request for Luveniq in July 2011.

The medicine was designated an orphan drug by the EMA in September, 2007 due to unmet need in its treatment area.

18th October 2011

Share

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
emotive.

emotive. is an award-winning healthcare communications agency working with leading global and EMEA companies in life sciences including medical device...

Latest intelligence

Report: Achieving launch excellence in the challenging healthcare markets of today
Our in-depth report is based on original data and expert interviews, which coupled with our own experience, ensures we give you the best recommendations for achieving launch success in challenging...
What is blockchain and why should i care - Richard Springham
Four Health - Emerging Technologies The power of blockchain lies in the fact it can prove that a unique event occurred at a certain time with out the need to...
NHS medicines optimisation milestone
Steve How, Paul Midgley and Oli Hudson, of the Wilmington Healthcare Consulting Team, explore the implications of Adalimumab’s recent European patent expiry...

Infographics